clinical trial · NCT07197307
Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Universität Münster·phase2·not yet recruiting·n = 120
Aggressive Diffuse Large B-cell LymphomaHigh-grade B-cell Lymphoma (HGBL)Follicular Lymphoma (FL) Grade 3BLoncastuximab Tesirine and Epcoritamab
brief summary
This is a phase II study designed to evaluate the toxicity and efficacy of the combination of loncastuximab tesirine and epcoritamab in patients with relapsed/refractory aggressive B-cell lymphoma. Chimeric antigen receptor (CAR)-T cell naive patients who have failed first-line therapy and patients who have received CAR-T cells as second-line therapy and experienced CAR-T failure will be eligible for inclusion.
started
Oct 15, 2025
primary completion
Jan 15, 2030
completion
Jan 15, 2030
last updated
Sep 29, 2025
detailed description
A total of 120 patients will be included. 60 days after 20 patients have started the therapy, a safety analysis will be performed to identify early and unexpected side effects of the combination therapy. An interim analysis will be conducted 6 months after recruitment of the 50th patient to check the effectiveness of the therapy.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol